Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Scar Gel Product Family Clinical Investigation

NCT: NCT07684573 · NOT_YET_RECRUITING

NCT IDNCT07684573
StatusNOT_YET_RECRUITING
Start Date2026-07
Completion2026-12
SponsorHanson Medical, Inc. (INDUSTRY)
First posted
Last updated

Brief Summary

The purpose of this PMCF investigation is to determine whether there are differences between the two formulations (Dermatix and Dermatix Ultra) in improving keloid and hypertrophic scars clinical symptoms and in the overall scar perception (including scar appearance and treatment perception). This PMCF investigation has been designed to address the conclusions of the latest CER \[PDPROJ-4-CE-R\] and the objectives. It has been chosen as an appropriate activity as it enables the collection of device-specific data on both device formulations and on the entire intended population. Moreover, the design of the PMCF investigation (single-center, parallel, open-label, two-arm, randomized controlled study) enables the direct comparison of the clinical performance/benefit between the two formulations.

Frequently Asked Questions

What is Scar Gel Product Family Clinical Investigation?

Scar Gel Product Family Clinical Investigation is a clinical trial registered under NCT07684573. Current status: NOT_YET_RECRUITING.

What is the status of NCT07684573?

The current status of NCT07684573 (Scar Gel Product Family Clinical Investigation) is: NOT_YET_RECRUITING.

When did Scar Gel Product Family Clinical Investigation start?

Scar Gel Product Family Clinical Investigation started on 2026-07.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.